Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03797261 · ClinicalTrials.gov registry record · Phase 1
A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies
A Phase 1 study, sponsored by AbbVie.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT03797261 is a Phase 1 study that was terminated before completion, run by AbbVie. The registered enrollment target is 9 participants.
The verdict
NCT03797261, a Phase 1 study, was terminated before completion, sponsored by AbbVie.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This dose-escalation study evaluating the safety, pharmacokinetics and preliminary efficacy of venetoclax in combination with AMG 176 in participants with relapsed or refractory acute myeloid leukemia (AML) and participants with Non-Hodgkin's lymphoma (NHL)/diffuse large B-cell lymphoma (DLBCL). This study will include a dose escalation phase to identify the maximum tolerated dose/recommended phase 2 dose (MTD/RPTD) of venetoclax plus AMG 176 as well as a dose expansion phase to confirm safety, explore efficacy, and confirm the suitability of the preliminary RPTD.
Interventions
- DRUG Venetoclax
- DRUG AMG 176
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2019-03-18 |
| Est. Completion | 2019-12-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03797261
The ClinicalTrials.gov registry entry for NCT03797261 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Venetoclax is the first listed.
NCT03797261 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03797261 about?
NCT03797261 is a clinical study titled "A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies". This dose-escalation study evaluating the safety, pharmacokinetics and preliminary efficacy of venetoclax in combination with AMG 176 in participants with relapsed or refractory acute myeloid leukemia (AML) and participants with Non-Hodgkin's lymphoma (NHL)/diffuse large B-cell lymphoma (DLBCL). Th...
What is the current status of trial NCT03797261?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2019-03-18. Estimated completion is 2019-12-30.
What interventions are being tested in trial NCT03797261?
The interventions under investigation include: Venetoclax (DRUG), AMG 176 (DRUG).
Who is sponsoring clinical trial NCT03797261?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.